Epidermal Growth Factor Receptor and K-ras Mutations in Patients With Stage III Non-Small Cell Lung Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00898924|
Recruitment Status : Completed
First Posted : May 12, 2009
Last Update Posted : June 29, 2016
RATIONALE: Collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study is looking at epidermal growth factor receptor mutations and k-ras oncogene mutations in patients with stage III non-small cell lung cancer.
|Condition or disease||Intervention/treatment|
|Lung Cancer||Genetic: molecular diagnostic method Genetic: mutation analysis|
- Determine the frequency of epidermal growth factor receptor (EGFR) and K-ras mutations in patients with stage III non-small cell lung cancer (NSCLC) treated on CALGB 30106.
- Correlate presence or absence of EGFR and/or K-ras mutations with radiographic response to treatment in these patients.
OUTLINE: Tissue samples are analyzed for epidermal growth factor receptor and K-ras mutations.
|Study Type :||Observational|
|Actual Enrollment :||60 participants|
|Official Title:||Evaluation of EGFR and K-ras Mutations in Patients With Stage III NSCLC Treated on CALGB 30106|
|Study Start Date :||November 2005|
|Actual Primary Completion Date :||March 2006|
|Actual Study Completion Date :||July 2010|
Tissue samples were collected from patients on Day 1, Cycle 1. Whole blood and serum samples were collected on Day 1 (Cycle 1), Day 1 (Cycle 3), post-radiotherapy ZD1839 and at progression.
Genetic: molecular diagnostic method
Genetic: mutation analysis
- Overall survival [ Time Frame: Up to 3 years ]
- Progression free survival [ Time Frame: Up to 3 years ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00898924
|Study Chair:||Pasi Janne, MD, PhD||Dana-Farber Cancer Institute|